slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 11,671-11,700
Pages 3,225
Rows per page 30
Component
11,671-11,700 of 96,741
127
The slide uses a red box to highlight specific text in the source material to support the claim of burying data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
134
The slide uses a direct quote and an abstract excerpt to build credibility for the argument that GH therapy has negative metabolic consequences.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
135
The slide uses direct excerpts from the FDA label to contrast with the company's reported clinical findings.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
145
The slide uses red annotations to re-interpret the company's original chart data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
151
The slide uses expert testimony to highlight a potential safety concern (edema) and suggests the company is downplaying or managing it in an unusual way.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
152
The slide uses direct quotes from a KOL to build a case against the safety of a drug (Vykat) in the PWS population.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
196
Includes chemical structures of Diazoxide and Choline to illustrate the 'salt' formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
220
The slide uses a quote from a trial investigator to expose a potential safety oversight in study design.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
224
The slide uses a Q&A transcript format to highlight negative sentiment from former employees.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
259
The slide uses a 'Miller XR' moniker to highlight the perceived over-reliance on a single individual.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
265
The slide uses a screenshot of a tweet as primary evidence to expose the subject's promotional behavior.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
299
The slide uses direct Q&A transcripts to highlight the investigator's negative sentiment and concerns about patient safety (diabetes/hyperglycemia).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
336
The slide uses a Q&A format to highlight the investigator's reluctance and admission of clinical risks.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
341
The slide uses direct quotes from an expert consultation to undermine the product's value proposition.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
364
The slide uses verbatim quotes from a consultation call to highlight a discrepancy between the company's risk management (handouts) and the physician's expectations of transient vs. permanent side effects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
376
The slide uses Q&A transcripts to undermine the value proposition of the company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
386
The slide presents a Q&A format where the expert questions the company's motives and the clinical rationale for their product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
404
The slide uses a summary paragraph followed by a direct quote, highlighting the expert's negative sentiment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
405
The slide uses direct quotes from an expert consultation to highlight the drug's perceived lack of efficacy and the barrier of administrative burden.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
01
The slide includes a call to action for stakeholders to contact the firm regarding an upcoming FDA Citizen Petition.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 2 hits
14
The slide uses a 'villain' narrative to frame the CEO's actions as potentially criminal, leveraging a recent legal precedent to build credibility.TransMedics (TMDX) · Scorpion Capital
Research note Short seller Beat · Critique of TransMedics Group Inc.2 hits
65
The slide uses a Q&A format to highlight alleged anti-competitive behavior (tying/bundling).TransMedics (TMDX) · Scorpion Capital
Research note Short seller 2 hits
66
The slide uses a Q&A format to present expert testimony as evidence of the company's alleged predatory practices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 2 hits
68
The slide uses a Q&A transcript format to build a narrative of extortion.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 2 hits
79
The slide uses a Q&A format to build credibility and expose operational inefficiencies.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 2 hits
85
The slide presents a Q&A style interview excerpt to support a claim of extortion/fraud.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 2 hits
89
The slide uses a highlight-heavy block quote to emphasize the alleged extortion and fraudulent billing.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 2 hits
90
The slide uses a testimonial to highlight a shift from a collaborative 'backyard relationship' to a profit-driven 'utilization at all costs' model.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 2 hits
97
The slide uses a quote to frame a potential conflict of interest or perverse incentive structure in organ transport.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 2 hits
99
This is a short-seller research note slide containing allegations of fraud and unethical business practices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 2 hits